Septic Shock clinical trials at UCSF
3 in progress, 2 open to eligible people
open to eligible people ages 18 years and up
Multicenter, prospective, phase 3 randomized non-blinded interventional trial of fluid treatment strategies in the first 24 hours for patients with sepsis-induced hypotension. The aim of the study is to determine the impact of a restrictive fluids strategy (vasopressors first followed by rescue fluids) as compared to a liberal fluid strategy (fluids first followed by rescue vasopressors) on 90-day in-hospital mortality in patients with sepsis-induced hypotension.
Fresno, California and other locations
open to eligible people ages 1 month to 17 years
SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hypothesized that adjunctive hydrocortisone will significantly reduce the proportion of children with poor outcomes, defined as death or severely impaired health-related quality of life (HRQL), as assessed at 28 days following study enrollment (randomization).
Oakland, California and other locations
Sorry, not yet accepting patients
Machine learning is a powerful method for creating clinical decision support (CDS) tools, but it requires training labels which reflect the desired alert behavior. In the Phase I work for this project, investigators have developed an encoding software called HindSight that examines discharged patients' electronic health records (EHR), identifies clinicians' sepsis treatment decisions and patient outcomes, and passes these labeled examples to an online algorithm for retraining InSight, a machine-learning-based CDS tool for real-time sepsis prediction. Although HindSight has been shown to be successful in improving the performance of InSight in retrospective work, it has yet to be validated in prospective settings; therefore, in this project, the clinical utility of HindSight will be assessed through a multicenter randomized controlled trial (RCT).